IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
iBio, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 28, 2026
$0.76−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $110.48M
- P/E (TTM)
- –
- Dividend yield
- –
iBio, Inc. revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceuticals (iBio, Inc.) [Member] | – | – | $1.88M | $1.10M | $1.55M | $2.02M | $407.00K | $271.00K | $893.00K | – | – | – |
| Bioprocessing (iBio CDMO) [Member] | – | – | $499.00K | $1.27M | $92.00K | $0 | $37.00K | $123.00K | $55.00K | – | – | – |
| Operating income | FY2026 | FY2025 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceuticals (iBio, Inc.) [Member] | – | – | -$29.19M | -$14.70M | -$4.15M | -$5.16M | -$5.28M | -$7.66M | -$7.49M | – | – |
| Bioprocessing (iBio CDMO) [Member] | – | – | -$20.50M | -$16.41M | -$9.86M | -$10.63M | -$8.95M | -$6.62M | -$2.40M | – | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative Revenues | $100.00K | $400.00K | – | – | – | – | – | – | – | – | 100.0% | -75.0% |
| Grant [Member] | – | – | – | – | – | – | $44.00K | $131.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of iBio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.